Pamela Vig compensation by year
Mirum Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2018 | FY2019 | FY2022 |
|---|---|---|---|
| Salary | $27,500 | $354,826 | $450,000 |
| Bonus | $0 | $155,300 | $0 |
| Stock awards | $0 | $0 | $158,700 |
| Option awards | $0 | $2,171,832 | $670,596 |
| Non-equity incentive | $0 | $0 | $216,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $0 | $0 | $12,200 |
| Total | $27,500 | $2,681,958 | $1,507,496 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mirum Pharmaceuticals, Inc. DEF 14A filed May 1, 2023, accession 0001140361-23-022054, and prior-year filings.
How this page was built: the Mirum Pharmaceuticals, Inc. filed document, accession 0001140361-23-022054. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 10,000 | $195,000 | — |
| RSU | 4,063 | $79,229 | — |
| Option | 60,000 | — | $15.87 |
| Option | 9,115 | — | $6.27 |
| Option | 14,084 | — | $19.24 |
| Option | 33,855 | — | $19.19 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Mirum Pharmaceuticals, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Mirum Pharmaceuticals’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Christopher Peetz | President and Chief Executive Officer | $4,402,664 |
| Peter Radovich | Chief Operating Officer | $1,561,446 |
| Lara Longpre | Chief Development Officer | $1,507,496 |
| Pamela Vig · this page | Head of Research and Development | $1,507,496 |
The full Mirum Pharmaceuticals compensation record
free company briefThis page is one person within Mirum Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Mirum Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mirum Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.